Cite
Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial.
MLA
Meyerhardt, Jeffrey A., et al. “Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial.” JAMA: Journal of the American Medical Association, vol. 325, no. 13, Apr. 2021, pp. 1277–85. EBSCOhost, https://doi.org/10.1001/jama.2021.2454.
APA
Meyerhardt, J. A., Shi, Q., Fuchs, C. S., Meyer, J., Niedzwiecki, D., Zemla, T., Kumthekar, P., Guthrie, K. A., Couture, F., Kuebler, P., Bendell, J. C., Kumar, P., Lewis, D., Tan, B., Bertagnolli, M., Grothey, A., Hochster, H. S., Goldberg, R. M., Venook, A., & Blanke, C. (2021). Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial. JAMA: Journal of the American Medical Association, 325(13), 1277–1285. https://doi.org/10.1001/jama.2021.2454
Chicago
Meyerhardt, Jeffrey A., Qian Shi, Charles S. Fuchs, Jeffrey Meyer, Donna Niedzwiecki, Tyler Zemla, Priya Kumthekar, et al. 2021. “Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial.” JAMA: Journal of the American Medical Association 325 (13): 1277–85. doi:10.1001/jama.2021.2454.